CCL

Összesen 2 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM105439
035-os BibID:(cikkazonosító)1940 (WoS)000902645500001 (Scopus)85144728705
Első szerző:Llanaj, Erand (táplálkozási epidemiológus)
Cím:Buckwheat and Cardiometabolic Health : a Systematic Review and Meta-Analysis / Llanaj Erand, Ahanchi Noushin Sadat, Dizdari Helga, Taneri Petek Eylul, Niehot Christa D., Wehrli Faina, Khatami Farnaz, Raeisi-Dehkordi Hamidreza, Kastrati Lum, Bano Arjola, Glisic Marija, Muka Taulant
Dátum:2022
ISSN:2075-4426
Megjegyzések:Buckwheat (BW) is suggested to have beneficial effects, but evidence on how it affects cardiometabolic health (CMH) is not yet established. We aimed to assess the effects of BW and/or its related bioactive compounds on cardiovascular disease (CVD) risk markers in adults. Five databases were searched for eligible studies. Observational prospective studies, nonrandomized or randomized trials were considered if they assessed BW, rutin or quercetin-3-glucoside intake and CVD risk markers. We adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting. We selected 16 human studies based on 831 subjects with mild metabolic disturbances, such as hypercholesterolemia, diabetes and/or overweight. Eight studies, investigating primarily grain components, were included in the meta-analyses (n = 464). High study heterogeneity was present across most of our analyses. Weighted mean difference (WMD) for subjects receiving BW supplementation, compared to controls, were - 0.14 mmol/L (95% CI: -0.30; 0.02) for total cholesterol (TC), -0.03 mmol/L (95% CI: -0.22; 0.16) for LDL cholesterol, -0.14 kg (95% CI: -1.50; 1.22) for body weight, -0.04 mmol/L (95% CI: - 0.09;0.02) for HDL cholesterol, -0.02 mmol/L (95% CI: -0.15; 0.11) for triglycerides and -0.18 mmol/L (95% CI: -0.36; 0.003) for glucose. Most of the studies (66.7%) had concerns of risk of bias. Studies investigating other CVD markers were scarce and with inconsistent findings, where available. Evidence on how BW affects CMH is limited. However, the available literature indicates that BW supplementation in mild dyslipidaemia and type 2 diabetes may provide some benefit in lowering TC and glucose, albeit non-significant. Our work highlights the need for more rigorous trials, with better methodological rigor to clarify remaining uncertainties on potential effects of BW on CMH and its utility in clinical nutrition practice.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Journal of Personalized Medicine. - 12 : 12 (2022), p. 1-19. -
További szerzők:Ahanchi, Noushin Sadat Dizdari, Helga Taneri, Petek Eylul Niehot, Christa D. Wehrli, Faina Khatami, Farnaz Raeisi-Dehkordi, Hamidreza Kastrati, Lum Bano, Arjola Glisic, Marija Muka, Taulant
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM099767
035-os BibID:(WoS)000737102800002 (Scopus)85122267234
Első szerző:Llanaj, Erand (táplálkozási epidemiológus)
Cím:Effect of oat supplementation interventions on cardiovascular disease risk markers : a systematic review and meta-analysis of randomized controlled trials / Llanaj Erand, Dejanovic Gordana M., Valido Ezra, Bano Arjola, Gamba Magda, Kastrati Lum, Minder Beatrice, Stojic Stevan, Voortman Trudy, Marques-Vidal Pedro, Stoyanov Jivko, Metzger Brandon, Glisic Marija, Kern Hua, Muka Taulant
Dátum:2022
ISSN:1436-6207
Megjegyzések:Purpose Oat supplementation interventions (OSIs) may have a beneficial effect on cardiovascular disease (CVD) risk. However, dietary background can modulate such effect. This systematic review assesses the effects of OSIs on CVD risk markers among adults, accounting for different dietary backgrounds or control arms. Methods We included randomized clinical trials (RCTs) that assessed the effect of oat, oat beta-glucan-rich extracts or avenanthramides on CVD risk markers. Results Seventy-four RCTs, including 4937 predominantly hypercholesterolemic, obese subjects, with mild metabolic disturbances, were included in the systematic review. Of these, 59 RCTs contributed to the meta-analyses. Subjects receiving an OSI, compared to control arms without oats, had improved levels of total cholesterol (TC) [weighted mean difference and (95% CI) - 0.42 mmol/L, (- 0.61; - 0.22)], LDL cholesterol [- 0.29 mmol/L, (- 0.37; - 0.20)], glucose [- 0.25 nmol/L, (- 0.36; - 0.14)], body mass index [- 0.13 kg/m(2), (- 0.26; - 0.01)], weight [- 0.94 kg, (- 1.84: - 0.05)], and waist circumference [- 1.06 cm, (- 1.85; - 0.27)]. RCTs on inflammation and/or oxidative stress markers were scarce and with inconsistent findings. RCTs comparing an OSI to heterogeneous interventions (e.g., wheat, eggs, rice, etc.), showed lowered levels of glycated haemoglobin, diastolic blood pressure, HDL cholesterol and apolipoprotein B. The majority of included RCTs (81.1%) had some concerns for risk of bias. Conclusion Dietary OSIs resulted in lowered levels of blood lipids and improvements in anthropometric parameters among participants with predominantly mild metabolic disturbances, regardless of dietary background or control. Further high-quality trials are warranted to establish the role of OSIs on blood pressure, glucose homeostasis and inflammation markers.
Tárgyszavak:Orvostudományok Egészségtudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:European Journal Of Nutrition. - 61 : 4 (2022), p. 1749-1778. -
További szerzők:Dejanovic, Gordana M. Valido, Ezra Bano, Arjola Gamba, Magda Kastrati, Lum Minder, Beatrice Stojic, Stevan Voortman, Trudy Marques-Vidal, Pedro Stoyanov, Jivko Metzger, Brandon Glisic, Marija Kern, Hua Muka, Taulant
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1